Beginning with its exatecan ADC, STRO-004, aimed at Tissue Factor, the biotechnology company situated in South San Francisco ...
Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...
Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as ...
It is easy to overlook how much coordination, time and dedication goes into running a college campus and ensuring everything ...
ImmunoPrecise announced a partnership with a biotechnology giant to develop ADCs and bispecific antibodies for the treatment ...
F5 CEO François Locoh-Donou spoke with CRN about F5 ADC 3.0 and the next generation of ADCs, AI and the cloud repatriation ...
Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A ...
Pharmaceutical Technology on MSN4d
WuXi XDC and AbTis collaborate on antibody-drug conjugatesThe partnership combines AbTis' AbClick site-selective conjugation platform with WuXi XDC's all-in-one development and ...
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with ...
Hosted on MSN19d
Pfizer sets sights on Summit’s bispecific in combo with its ADCsPfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s Keytruda-challenging ivonescimab in combination with several of its antibody-drug conjugates (ADCs).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback